Skip to main content
Erschienen in: Annals of Surgical Oncology 8/2016

23.03.2016 | Breast Oncology

Post-mastectomy Radiation: Should Subtype Factor into the Decision?

verfasst von: Adena S. Scheer, MD, MSc, Francis S. W. Zih, MD, MSc, Ellen Maki, PhD, C. Anne Koch, MD, PhD, David R. McCready, MD, MSc, FRCSC, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Traditional indications do not factor molecular subtype into the decision making for post-mastectomy radiation (PMRT). We sought to determine whether constructed subtype was associated with receipt of PMRT in an academic cancer center and to assess differences in locoregional recurrence (LRR) by constructed subtype.

Methods

Patients treated with mastectomy as the primary surgical therapy were identified. Univariate and stepwise multivariate logistic regression analyses examined the association between covariates and PMRT. Kaplan–Meier estimates for the time to either the earlier of LRR or last follow-up were obtained for each subtype, and Cox proportional hazards regression examined the effect of covariates on time to LRR in both univariate analyses and stepwise multivariate analysis.

Results

Overall, 884 patients with invasive breast cancer who underwent a primary mastectomy between January 2002 and May 2012 were included in the study. A total of 359 patients (41.6 %) received PMRT. Compared with other subtypes, triple negative (TN; HR−/HER2−) cancers were more likely to be smaller (95 % T1/T2; p = 0.02) and have a lower nodal burden (N0 65 %; p < 0.0001). On multivariate analysis, age < 50 years, lymphovascular invasion (LVI), T stage, N stage, and close or positive margins remained significantly associated with PMRT, while constructed subtype was not associated with PMRT. Compared with all other subtypes, TN had the highest rate of LRR [hazard ratio (HR) 5.70; p < 0.0001]. On multivariable analysis, TN status, LVI, and not receiving chemotherapy were significantly associated with LRR.

Conclusions

Despite significant differences in LRR by constructed subtype, receptor status does not appear to be associated with the receipt of PMRT. In our series, TN cancers had the highest risk of LRR despite their relatively smaller size and limited nodal disease.
Literatur
1.
Zurück zum Zitat EBCTCG Early Breast Cancer Trialists’ Collaborative Group. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127–35.CrossRef EBCTCG Early Breast Cancer Trialists’ Collaborative Group. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127–35.CrossRef
2.
Zurück zum Zitat Whelan TJ, Olivotto I, Ackerman I, et al. NCIC-CTG MA.20: an intergroup trial of regional nodal irradiation in early breast cancer [abstract]. J Clin Oncol. 2011; 29 (18 Suppl): LBA1003. Whelan TJ, Olivotto I, Ackerman I, et al. NCIC-CTG MA.20: an intergroup trial of regional nodal irradiation in early breast cancer [abstract]. J Clin Oncol. 2011; 29 (18 Suppl): LBA1003.
3.
Zurück zum Zitat Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trail. N Engl J Med. 1997;337:949–955.CrossRefPubMed Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trail. N Engl J Med. 1997;337:949–955.CrossRefPubMed
4.
Zurück zum Zitat Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer cooperative Group DBCG 82c randomized trial. Lancet. 1999;353:1641–1648.CrossRefPubMed Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer cooperative Group DBCG 82c randomized trial. Lancet. 1999;353:1641–1648.CrossRefPubMed
5.
Zurück zum Zitat Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97:116–126.CrossRefPubMed Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97:116–126.CrossRefPubMed
6.
Zurück zum Zitat Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1539–1569.PubMed Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1539–1569.PubMed
7.
Zurück zum Zitat Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005;23:7350–7360.CrossRefPubMed Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005;23:7350–7360.CrossRefPubMed
8.
Zurück zum Zitat Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264–271.CrossRefPubMed Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264–271.CrossRefPubMed
9.
Zurück zum Zitat Nguyen PL, Tagbian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER2 is associated with local and distant recurrence after breast conserving therapy. J Clin Oncol. 2008;26: 2373–2378.CrossRefPubMed Nguyen PL, Tagbian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER2 is associated with local and distant recurrence after breast conserving therapy. J Clin Oncol. 2008;26: 2373–2378.CrossRefPubMed
10.
Zurück zum Zitat Dominici LS, Mittendorf EA, Wang X, et al. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Br Cancer Res. 2012;14:R82.CrossRef Dominici LS, Mittendorf EA, Wang X, et al. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Br Cancer Res. 2012;14:R82.CrossRef
11.
Zurück zum Zitat Caudle AS, Yu TK, Tucker SL. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Br Cancer Res. 2012;14:R83.CrossRef Caudle AS, Yu TK, Tucker SL. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Br Cancer Res. 2012;14:R83.CrossRef
12.
Zurück zum Zitat Giordano SH, Temin S, Kirshner JJ, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014;32:2078–2099.CrossRefPubMed Giordano SH, Temin S, Kirshner JJ, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014;32:2078–2099.CrossRefPubMed
13.
Zurück zum Zitat Partridge AH, Rumble RB, Carey LA, et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Practice Guideline. J Clin Oncol. 2014;32:3307–3329.CrossRefPubMed Partridge AH, Rumble RB, Carey LA, et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Practice Guideline. J Clin Oncol. 2014;32:3307–3329.CrossRefPubMed
14.
Zurück zum Zitat Moran, M. Should triple-negative breast cancer (TNBC) subtype affect local-regional therapy decision making? Lancet Oncol. 2015;16:e113–22.CrossRefPubMed Moran, M. Should triple-negative breast cancer (TNBC) subtype affect local-regional therapy decision making? Lancet Oncol. 2015;16:e113–22.CrossRefPubMed
15.
Zurück zum Zitat Kyndi M, Sorensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER2, and response to post-mastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:1419–1426.CrossRefPubMed Kyndi M, Sorensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER2, and response to post-mastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:1419–1426.CrossRefPubMed
16.
Zurück zum Zitat Abdulkarim BS, Cuartero J, Hanson J, et al. Increased risk of locoregional recurrence for women with T1-2N0 triple negative breast cancer treated with modified radical mastectomy without adjuvant radiation compared with breast conservation therapy. J Clin Oncol. 2011;29:2852–2858.CrossRefPubMed Abdulkarim BS, Cuartero J, Hanson J, et al. Increased risk of locoregional recurrence for women with T1-2N0 triple negative breast cancer treated with modified radical mastectomy without adjuvant radiation compared with breast conservation therapy. J Clin Oncol. 2011;29:2852–2858.CrossRefPubMed
17.
Zurück zum Zitat Foulkes WD, Reis-Filho JS, Narod SA. Tumour size and survival in breast cancer: a reappraisal. Nat Rev. 2010;7:348–353. Foulkes WD, Reis-Filho JS, Narod SA. Tumour size and survival in breast cancer: a reappraisal. Nat Rev. 2010;7:348–353.
18.
Zurück zum Zitat Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes and survival in the Carolina breast cancer study. JAMA. 2006;295:2492–2502.CrossRefPubMed Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes and survival in the Carolina breast cancer study. JAMA. 2006;295:2492–2502.CrossRefPubMed
19.
Zurück zum Zitat Foulkes WD, Smith IE, Reis-Filho JS, et al. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–1948.CrossRefPubMed Foulkes WD, Smith IE, Reis-Filho JS, et al. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–1948.CrossRefPubMed
20.
Zurück zum Zitat Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–4434.CrossRefPubMed Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–4434.CrossRefPubMed
21.
Zurück zum Zitat Hattanqadi-Gluth JA, Wo JY, Nguyen PL, et al. Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2012;82:1185–91.CrossRef Hattanqadi-Gluth JA, Wo JY, Nguyen PL, et al. Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2012;82:1185–91.CrossRef
22.
Zurück zum Zitat Wo JY, Taghaian AG, Nguyen PL, et al. The association between biological subtype and isolated regional nodal failure after breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2010;77:188–196.CrossRefPubMed Wo JY, Taghaian AG, Nguyen PL, et al. The association between biological subtype and isolated regional nodal failure after breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2010;77:188–196.CrossRefPubMed
23.
Zurück zum Zitat Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28:1684–91.CrossRefPubMed Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28:1684–91.CrossRefPubMed
24.
Zurück zum Zitat Truong PT, Olivotto IA, Kader HA, et al. Selecting breast cancer patients with T1-T2 tumours and one to three positive axillary nodes at high post-mastectomy locoregional risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61:1337–1347.CrossRefPubMed Truong PT, Olivotto IA, Kader HA, et al. Selecting breast cancer patients with T1-T2 tumours and one to three positive axillary nodes at high post-mastectomy locoregional risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61:1337–1347.CrossRefPubMed
25.
Zurück zum Zitat Chen X, Yu X, Chen J, et al. Analysis in early stage triple negative breast cancer treated with mastectomy without adjuvant radiotherapy: patterns of failure and prognostic factors. Cancer. 2013;119:2366–74.CrossRefPubMed Chen X, Yu X, Chen J, et al. Analysis in early stage triple negative breast cancer treated with mastectomy without adjuvant radiotherapy: patterns of failure and prognostic factors. Cancer. 2013;119:2366–74.CrossRefPubMed
26.
Zurück zum Zitat Gabos Z, Thoms J, Ghosh S. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Res Treat. 2010;124:187–194.CrossRefPubMed Gabos Z, Thoms J, Ghosh S. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Res Treat. 2010;124:187–194.CrossRefPubMed
27.
Zurück zum Zitat Steward LT, Gao F, Taylor MA, Margenthaler JA. Impact of radiation therapy on survival in patients with triple-negative breast cancer. Oncol Lett. 2014;7:548–52.PubMed Steward LT, Gao F, Taylor MA, Margenthaler JA. Impact of radiation therapy on survival in patients with triple-negative breast cancer. Oncol Lett. 2014;7:548–52.PubMed
28.
Zurück zum Zitat Adkins FC, Gonzalez-Anqulo AM, Lei X, et al. Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol. 2011;18:3164–73.CrossRefPubMedPubMedCentral Adkins FC, Gonzalez-Anqulo AM, Lei X, et al. Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol. 2011;18:3164–73.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Zumsteg ZS, Morrow M, Arnold B, et al. Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer. Ann Surg Oncol. 2013;20:3469–76.CrossRefPubMed Zumsteg ZS, Morrow M, Arnold B, et al. Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer. Ann Surg Oncol. 2013;20:3469–76.CrossRefPubMed
30.
Zurück zum Zitat Chen X, Yu X, Chen J, et al. Radiotherapy can improve disease-free survival rate in triple-negative breast ancer patients with T1-T2 disease and one to three positive lymph nodes after mastectomy. Oncologist. 2013;18:141–7.CrossRefPubMedPubMedCentral Chen X, Yu X, Chen J, et al. Radiotherapy can improve disease-free survival rate in triple-negative breast ancer patients with T1-T2 disease and one to three positive lymph nodes after mastectomy. Oncologist. 2013;18:141–7.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Li Q, Wu S, Zhou J, et al. Risk factors for locoregional recurrence after postmastectomy radiotherapy in breast cancer patients with four or more positive axillary lymph nodes. Curr Oncol. 2014;21:e685–690.CrossRefPubMedPubMedCentral Li Q, Wu S, Zhou J, et al. Risk factors for locoregional recurrence after postmastectomy radiotherapy in breast cancer patients with four or more positive axillary lymph nodes. Curr Oncol. 2014;21:e685–690.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–67.CrossRefPubMedPubMedCentral Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–67.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Albert JM, Kim KW, Cao C, et al. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther. 2006;5:1183–1189.CrossRefPubMed Albert JM, Kim KW, Cao C, et al. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther. 2006;5:1183–1189.CrossRefPubMed
35.
Zurück zum Zitat Wang SL, Li YX, Zhang BN, et al. Epidemiologic study of compliance to post-mastectomy radiation therapy guidelines in breast cancer patients in China between 1999 and 2008. Pract Radiat Oncol. 2013;3(3):209–15.CrossRefPubMed Wang SL, Li YX, Zhang BN, et al. Epidemiologic study of compliance to post-mastectomy radiation therapy guidelines in breast cancer patients in China between 1999 and 2008. Pract Radiat Oncol. 2013;3(3):209–15.CrossRefPubMed
36.
Zurück zum Zitat Punglia RS, Hughes ME, Edge SB, et al. Factors associated with guideline-concordant use of radiotherapy after mastectomy in the national comprehensive cancer network. Int J Radiat Oncol Biol Phys. 2008;72(5):1434–40.CrossRefPubMedPubMedCentral Punglia RS, Hughes ME, Edge SB, et al. Factors associated with guideline-concordant use of radiotherapy after mastectomy in the national comprehensive cancer network. Int J Radiat Oncol Biol Phys. 2008;72(5):1434–40.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Chu QD, Caldito G, Miller JK, Townsend B. Postmastectomy radiation for n2/n3 breast cancer: factors associated with low compliance rate. J Am Coll Surg. 2015;220(4):659–69.CrossRefPubMed Chu QD, Caldito G, Miller JK, Townsend B. Postmastectomy radiation for n2/n3 breast cancer: factors associated with low compliance rate. J Am Coll Surg. 2015;220(4):659–69.CrossRefPubMed
Metadaten
Titel
Post-mastectomy Radiation: Should Subtype Factor into the Decision?
verfasst von
Adena S. Scheer, MD, MSc
Francis S. W. Zih, MD, MSc
Ellen Maki, PhD
C. Anne Koch, MD, PhD
David R. McCready, MD, MSc, FRCSC, FACS
Publikationsdatum
23.03.2016
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 8/2016
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-5071-5

Weitere Artikel der Ausgabe 8/2016

Annals of Surgical Oncology 8/2016 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.